Study Information

Alliance Study ID: NCCTG-N083E

NCT Study ID (ClinicalTrials.gov): NCT00820872

Alliance Committee: Breast Cancer

Disease or Cancer Type: Breast Cancer

Alliance Study Chair: Edith A. Perez, MD

Status: COMPLETED


Study Description

RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving docetaxel together with carboplatin, trastuzumab, and lapatinib may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects of giving docetaxel together with carboplatin, trastuzumab, and lapatinib in treating patients with early stage breast cancer.

Related Publications

For publications related to this and other clinical trials, visit the Alliance Publications Application.

Data Sources & Contacts

Related Alliance Trials

Related News